Tarsus Pharmaceuticals announced its management will participate in three upcoming investor conferences: Guggenheim Healthcare Conference on Nov 10, Jefferies Global Healthcare Conference on Nov 18-19, and Piper Sandler Healthcare Conference on Dec 1. These events include fireside chats where the company will discuss its progress and pipeline, including its FDA-approved eye care product XDEMVY® and other treatments in development. The presentations aim to update investors on Tarsus's growth and innovation in eye care and other therapeutic areas.
Tarsus Pharmaceuticals' upcoming investor conference participation is contextually framed by Pluang's health sector data. As of Nov 06, 2026 04:11 WIB, 16 of 150 health-sector US stocks on Pluang rose while 134 fell. Notable movers include Guardant Health Inc. at USD 129.81 with a -23.00% change, Inovio Pharmaceuticals Inc at USD 1.26 down 22.22%, and Cassava Sciences Inc at USD 0.46 down 21.02%.
Grupo Aeroportuario del Sureste (ASUR) reported a 0.9% decrease in total passenger traffic for October 2026 compared to the previous year, totaling 9.3 million passengers. While Colombia, Puerto Rico, Brazil, and Ecuador saw modest increases in domes...
BioAge Labs initiated dosing in its Phase 2 trial (QUELL-DME) for BGE-102, an oral NLRP3 inhibitor aimed at treating diabetic macular edema, with topline results expected in late 2027. The company also completed enrollment in a Phase 2 cardiovascular...
Vaalco Energy announced a quarterly cash dividend of $0.0625 per share for Q4 2026, payable on December 22, 2026, to shareholders of record as of November 20, 2026. This marks the company's 20th consecutive quarterly dividend, reflecting its strong c...
Mercer International reported a significant improvement in its third quarter 2026 Operating EBITDA, narrowing losses to negative $2.9 million from negative $28.1 million a year earlier, driven by cost savings and government grants. The company has en...
Ameren Corporation reported third quarter 2026 GAAP diluted EPS of $2.42, up from $2.35 in 2025, driven by infrastructure investments and higher electric sales. The company raised its 2026 earnings guidance to $5.35-$5.55 per share and set 2027 guida...
